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Introduction:  FNAIT is a condition were the immune system of a pregnant woman is 
activated and produces antibodies against an unborn child’s blood platelets. 
The mechanisms behind the activation of the B-cells remain unknown. The 
purpose of this research was to look at antigen-specific humoral immune 
responses associated with FNAIT. Our goal was to activate antigen-specific B-
cells in vitro.  
Method:  In order to establish a cell culture system to study activation of memory B-cells 
in vitro, PBMC from three donors were cultured with cytokines, antigen and 
EL-4-B5. B-cells were sorted with MACS, and flow cytometry was performed 
to analyse cell populations and to identify and isolate antibody-secreting 
plasmablasts. B-cell activation was confirmed by antibody production 
measured with ELISA, and/or detection of plasmablasts with ELISpot.  
Results: Cultures showed increased number of plasmablasts producing IgG antibodies. 
EL-4-B5 was most important to activate and stimulate B-cells, and antigen had 
a synergic effect. Only a limited number of antigen-specific plasmablasts and 
antibodies were detected. 
Conclusion:  Isolated B-cells in culture with antigen, cytokines and CD40L+ EL-4-B5 cells, 
differentiated to plasmablasts producing IgG, which were successfully 
identified with flow cytometry. Further research is needed to develop a method 
to activate antigen-specific B-cells.  
 









ALP: Alkaline phosphatase  
APC (cell): Antigen presenting cell 
APC (fluorochrome): Allophycocyanin 
BAFF: B-cell activating factor 
B-cell: B lymphocyte 
BCIP/NBT: Nitro-blue tetrazolium chloride/5-bromo-4-chloro-3-indolyphosphate p-toluidine 
salt  
BSA: Bovine serum albumin 
EBV: Epstein-Barr virus 
ELISA: Enzyme linked immunosorbent assay 
FACS: Fluorescence activated cell sorting 
FBS: Fetal bovine serum 
FNAIT: Fetal neonatal alloimmune thrombocytopenia 
FITC: Fluorescein isothiocyanate 
HPA: Human platelet antigen 
IL: Interleukin  
IMDM: Iscove’s modified Dulbecco’s medium  
IU: International units 
MACS: Magnetic-activated cell sorting 
MHC: Major histocompatibility complex 
PBMC: Peripheral blood mononuclear cells 
PBS: Phosphate buffered saline 
PBSA: PBS + BSA 
PE: Phycoerythrin 
PE-A-F610: Phycoerythrin alexa fluor 610 
PMN: Polymorphonuclear (-cells) 
PNPP: P.Nitrophenylphosphate 
RBC: Red blood cells 
T-cell: T-lymphocyte 
TNF: Tumor necrosis family 





The immune system is essential for human life (1). We are surrounded by microbes every day 
and the immune system is our protector. It is simple and universal as well as complex and 
specific. The immune system is divided into the innate and adaptive system. The innate 
system consists of cells such as macrophages, monocytes and granulocytes, and many 
proteins and molecules, that respond quickly and faces all antigens the same way (1). The 
adaptive system reacts specifically to each antigen, this process takes time to react. The cells 
in the adaptive system are mainly the lymphocytes which are divided into the T-lymphocyte 
(or T-cell) and B-lymphocyte (B-cell). Memory cells in the adaptive system have the ability 
to remember an antigen and respond faster and greater upon repeated encounter. The immune 
system may also cause problems (1). In the condition fetal and neonatal alloimmune 
thrombocytopenia (FNAIT)  the immune system of a pregnant woman may cause severe 
disease or death to an unborn child (2). In FNAIT, B-cells in the mother’s immune system are 
activated and create antibodies against the foreign antigens of the fetal platelets (2). The 
purpose of this research was to investigate antigen-specific humoral immune responses 
connected to FNAIT.  
The B-cell is activated by interacting with other cells and molecules (1, 3). The antigen 
presenting cell (APC) binds antigens in the tissues and present processed antigen-peptides on 
a molecule called major histocompatibility complex (MHC). Interaction between T-cell 
receptors and MHC is important for activation of T-cells. B-cells bind antigen and display 
antigen-peptides on MHC. The activated T-cell recognises the MHC on B-cell, and help 
activate B-cells through secreting cytokines and expressing a molecule called CD40 ligand 
(CD40L)(1). CD40L expressed on activated T-cells binds to a CD40 receptor on the B-cell 
and enhances B-cell survival and the production of cytokines. Cytokines are proteins 
produced by cells to affect other cells, and bind to specific receptors on the target cell to 
enhance a reaction (1). After activation, the B-cell differentiates into a plasma cell which 
produces antibodies, also known as immunoglobulins (Ig) (1). Antibodies are B-cell receptors 
that binds to antigens, e.g. bacteria. The antibodies can activate the immune system, inactivate 
the antigen (neutralization) or tag the antigen so that other cells destroy it (opsonization). 
Tetanus toxoid (TT) is an antigen derived from the bacteria Clostridium tetani (4). When 




TT is the inactivated toxin, and TT activates the immune system resulting in production of 
antibodies against TT (anti-TT). TT is the basis for the tetanus vaccine (4).  
The objective in this study is to develop a method for activating B-cells in vitro in order to 
further investigate the immunology of FNAIT. This will be done by multiple lab experiments 
connected to B-cell activation and production of antibodies. FNAIT is a not a common 
condition, and blood samples from affected patients are rare. Therefore, another antigen, 
tetanus toxoid (TT), was used as a test system. We predict that knowledge of B-cells activated 
by TT can directly be transferred to FNAIT. Our aim was to be able to use TT and T-cells 
expressing CD40L to activate B-cells. We looked at antigen-specific activation, and what 
combination of stimulating agents were the most beneficial. Our research started with blood 
















3 Relevant background information 
The immune system is a collection of cells and proteins working together to prevent illness 
(1). Lymphocytes are responsible for the adaptive immune system, and the B- and T-cells are 
activated by specific antigens. Antigens activate naïve cells and they differentiate into effector 
cells and memory cells. Early after differentiation the cells are called blasts (e.g. plasmablast, 
lymphoblast) and later they become the mature cell (e.g. plasmacyte or plasma cell and 
lymphocyte). Effector B-cells are the antibody producing plasma cells responsible for 
humoral immunity (immunity due to antibodies)(1).  
B-cells are activated by cell-to-cell contact and cytokines (1, 3), see figure 4.1. B-cells have 
B-cell receptors that interact with antigen and processed antigen-peptides are presented on 
MHC to be recognised by T-cells. Crosslinking of antigens are shown to increase antigens 
stimulating effects (5, 6). Antigen recognized by T-cell receptors activate T-helper cells to 
display CD40L. CD40 receptor on B-cells recognize CD40L on activated T-cells, and this T-
cell to B-cell contact is found to be essential in B-cell activation (7, 8). The effect is strongest 
when both cells are activated by the same antigen, called linked recognition (3). Both B- and 
T-cells will release cytokines to help stimulate the opposite cell (1).  
 
Figure 4.1: Simplified figure of B-cell activation. 
Antigen is processed by B-cell and APC and presented on MHC. APC activates the T-cell to 
display CD40L. CD40L on activated T-cell interact with CD40 on B-cell. Cytokines such as 
BAFF and IL-21 stimulate to activation of B-cell. When activated, B-cell differentiates into the 






Cytokines bind specific surface receptors on target cells and enhance intracellular reactions, 
e.g. stimulation to enter cell cycle and proliferate (1). Cytokines produced by lymphocytes are 
called lymphokines or interleukins (IL) (1). Interleukin 21 (IL-21) is involved in innate and 
adaptive immune responses (9). It is produced by T-cells and has a central role in early B-cell 
responses, plasma cell differentiation and development of immunoglobulins (3, 9). BAFF (B-
cell activating factor) is a cytokine in the TNF (tumor necrosis factor) family, and promotes 
B-cell survival through interaction with the BAFF-receptor (3). Cytokines can also have 
regulatory effects, e.g. IL-21 can enhance cell death (apoptosis) under some conditions (9). 
CpG are synthetic DNA strands mimicking DNA from bacteria, and are found to stimulate 
immune responses (5, 10-12).  
Antibodies, or immunoglobulins, are cell surfaced or secreted B-cell receptors that bind to 
antigens (1). All antibodies consist of the same structure with Fab (Fragment antigen binding) 
and Fc (fragment crystallizable), see figure 4.2. The Fab binds to the antigen and consists of 
heavy- and light-chains. Fab has a constant region and a variable region with antigen-binding 
site specific for each antigen. The Fc fragment binds to Fc-receptors on immune cells, e.g. 
macrophages. It consists of two heavy chains which 
make the different classes of Ig´s (1).  
Immunoglobulins (Ig) are divided in 5 classes or 
isotypes; IgM, IgA, IgG, IgD and IgE (1). Young 
(naïve) plasma cells produce IgM, and IgM is 
therefore the first antibody to be produced in a 
response to a new antigen. IgM is attached to naïve 
B-cells in monomeric form or circulates in 
pentameric form. Later in the immune response there 
is an isotype shift from IgM to the other isotypes. IgA 
is the main antibody on the mucosa and there is some 
monomeric IgA in blood. IgG is produced by memory 
cells in the secondary immune response. IgG is 
divided into 4 subgroups (IgG1-IgG4) and is the most 
frequent immunoglobulin in blood. IgE is mostly bound by mast cells. The function of IgD is 
unknown (1). IgG is most important for secondary immune responses, as for FNAIT.  
Figure 4.2: Structure of immunoglobulins. 
Immunoglobulins consist of Fab and Fc 
fragments. Fab is divided in a variable and 
constant region and contain light and heavy 
chains. The variable region has antibody-
binding site specific for each antigen. Fc 
binds to immune cells. The figure is based on 





Immunoglobulins are antigen-specific (1). Memory B-cells will only be activated by the 
antigen matching its specific receptor. Interaction with the receptor cause the memory B-cell 
to differentiate and produce monoclonal antibodies (1). It is possible to activate B-cells 
without a specific antigen if the other stimulants are strong, but this activation will be 
unspecific and produce polyclonal antibodies (3). Because they are specific, antibodies can be 
used to detect and sort antigens from a compound. E.g. B-cells have antigens on the surface 
such as CD19 and CD22, and anti-CD19 and anti-CD22 can therefore be used to detect B-
cells. Likewise are anti-CD38 and anti-CD27 used to detect plasmablasts (5).  
FNAIT is a disorder caused by activation of B-cells and production of antibodies (2). 
Differences in maternal and fetal platelet antigens results in a maternal humoral immune 
response. The production and binding of IgG to fetal thrombocytes leads to thrombocytopenia 
and may cause severe bleeding and death. FNAIT is estimated in 0,5-1,5 per 1000 live births 
(2) and is a major cause of severe thrombocytopenia. >75% of FNAIT in the Caucasian 
population is caused by antibodies against human platelet antigen 1a (HPA-1a). More 
specifically, the antibodies bind to a glycoprotein called GPIIbIIIa (αIIbβ3 integrin), one of 
two major receptors on the fetal thrombocyte surface (2). There is no screening test and the 
condition is usually discovered when symptoms are severe. Preventing measures are only 
performed when the condition is known from a previous pregnancy. Treatment options are 
limited to general approaches (4). Details of the maternal immune response leading to FNAIT 
remains largely unknown*. There is no in vitro model well suited for further experimenting 
B- and T-cell interactions leading to antibody secretion in the context of FNAIT. 
Experiments ex vivo mimic interactions in vivo. PBMC is a collection of the major immune 
cells such as lymphocytes (13), and will provide the B-cells for the experiments. EL-4-B5 is a 
mutant clone of T-cells from mouse (14) that continuously display CD40L (15). Cytokines 
such as BAFF and IL-21, and CpG will be used to stimulate cells. TT is used as antigen to 
stimulate B-cells to produce anti-TT specific antibodies. Tetanus is a well-documented 
antigen, and commonly used in immunological experiments. It is part of the standard 
vaccination program in many countries (4), and samples from donors with immunity to TT 
are therefore easy to acquire. Vaccination must be repeated to maintain a protective level of 
anti-TT antibodies in serum above 0,01 IU/mL (4). Tetagam is synthetic immunoglobulins 





The experiments were performed at the immunological lab at the University of Tromsø (UiT) 
and the University Hospital of Northern Norway (UNN). Flow cytometry was performed at 
the Advanced Microscopy Core Facility (AMCF), UiT. Basic lab knowledge is expected for 
performing the experiments. A list of materials can be found in the appendix.  
4.1 Isolating PBMC from buffy coat 
PBMC was withdrawn from buffy coats received from the blood bank at UNN. The blood 
bags were chosen randomly, the donors are anonymous adults and expected healthy. All 
donors had given a general consent that their blood could be used for scientific purposes. The 
donors were marked donor 1, 2 and 3, this will also apply for the PBMC (e.g. PBMC1 from 
donor 1). Plasma was transferred from each donor in the same step as PBMC. 
The contents of buffy coats were distributed in two 50 mL vials and diluted 1:1 in PBS 
(phosphate buffered saline). 12 mL 1.077 g/mL density gradient 
medium (Lymphoprep, Stemcell Technologies, Vancouver, 
Canada) was transferred to four 50 mL vials. ¼ of the diluted 
buffy coat solution was carefully layered on top of the density 
gradient medium in each vial to prevent mixing. The vials were 
centrifuged for 30 minutes at 800 x g, 24 degrees, without 
breaks. The interface containing the PBMC was extracted as 
shown in figure 5.1 using a plastic Pasteur pipette.  
The PBMC was washed three times using the following 
procedure: PBSA 0,2% (PBS + 0,2% BSA (bovine serum 
albumin)) was added to reach 45 mL, then centrifuged 10 
minutes at 250 x g. Centrifugation forced the cells to the 
bottom of the vial, the supernatant was discarded by 
decantation into a bucket while the cells remained at the 
bottom of the vial. The cell pellet was detached from the 
bottom by flicking the vial. Cell culture medium (IMDM 
(Iscove’s modified Dulbecco’s medium) + 10% FBS (fetal bovine serum)) was added.  
Figure 5.1: Layers of buffy coat after 
density gradient medium (Lymphoprep) 
is added and centrifuged.  
Lymphoprep separate PBMC from RBC 
and PMN’s.  
The pipette point to the layer of PBMC 
extracted for further experimental use. 





4.2 Counting cells using a hemocytometer 
10 L of cell sample was transferred to the hemocytometer using a micropipette. If the 
solution contained a high number of cells, the solution was diluted. For 1:10 dilution, 90 L 
medium was transferred to a vial and 10 L cell sample added. After mixing, 10 L of diluted 
cell solution was transferred to the hemocytometer.  
The number of cells were counted using a microscope. The Burker chamber consists of 9 big 
squares, divided in 16 medium squares, each divided in 16 small squares. One medium square 
is 1 𝑚𝑚2, and the chamber is 0,1 mm deep. One medium square is therefore 1 𝑚𝑚2 x 0,1 
mm = 0,1 𝑚𝑚3 = 0,1 L. Multiplying by 10 000 gives the number of cells per mL. For 
example, a count of 40 cells in 16 small or one medium square: 40 cells/mm2 = 40 cells/0,1L 
= 400 000 cells/mL. If dilutions were made, this was accounted for, e.g. x 10 for 1:10 
dilution. The count was multiplied with the number of mL cell sample to know the total cell 
count in the flask.  
The hemocytometer is an easy method for estimating cell concentration. The method can 
however be incorrect because of uneven distribution of cells on the hemocytometer. To ensure 
a representative count, the mean value in 5-6 different squares was used for calculations. The 
cells can also be uneven distributed in the cell solution, although cells were detached and 
mixed before transferring to the hemocytometer. There might also be other cells in the 
solution giving a false high estimate, e.g. red blood cells, which can be difficult to distinguish 
from lymphocytes by 100 - 400 x magnification light microscopy.  
 
4.3 Preparations for freezing cells 
Cells were redistributed in a smaller volume by centrifuging 5 minutes at 350 x g and the 
surface solution discarded. Freezing medium (90% FBS, 10% IMDM) was added to the cell 
pellet and mixed before distributed in cryovials safe for freezing. The vials were put in a 
cooled box designed for freezing cells, with a separate chamber containing isopropanol. The 
box was then placed in freezer at -70°C. The cells could at any time be removed from freezer 
and used for experiments. The vials were defrosted quickly by vigorous shaking under warm 




while inverting the vial. The content was immediately diluted at least 1:10 in cold cell culture 
medium, centrifuged 4 minutes at 400 x g, decanted, and the cells suspended in cell culture 
medium for over-night recovery in tissue culture flasks at 37°C. 
 
4.4 Preparations for cell culture 
Three different cultures were made for the research. Here follows a general description of the 
preparations. For more information of each culture, see results and the appendix. Sterile 
ELISA plates consisting of 96 wells were used for the cultures. The wells ensured good 
environment for cells and antigens to interact, and it was possible to remove surface solution 
for analysing without interrupting the cells. The supernatants could be stored in fridge at 4 °C 
until analysing.  
Cells: Cells were counted and resuspended in medium. For PBMC/B-cells, calculations were 
made to gain approximately 20 000 B-cells per well. EL-4-B5 was irradiated to prevent 
further growth, and calculations made to gain 40 000 EL-4-B5 cells per well. Medium was 
added to gain 50 µL of cell suspension per well.  
Antigen: The antigens were sterile filtered with a 0,2 m filter before use. The tetanus toxoid 
(TT) concentration differed, for the first culture 50 µL of 4-64 ng/mL was added to wells. For 
the two last cultures 100 µL of 1,75 µg/mL TT was added to B-cells. The cells were placed on 
ice for 20 minutes. The leftover antigens were washed off using the following method: 10 mL 
PBSA 0,2% was added to each sample and then centrifuged 4 minutes at 400 x g. The 
supernatant was discarded, and the cell pellet detached by flicking the vial. If purified anti-TT 
antibody (tetagam) were used, TT was first added and washed off before tetagam was added. 
50 µL of 2,5 IU/mL tetagam were added to B-cells, then placed on ice for 20 minutes. The 
leftover tetagam did not need to be washed off.  
Cytokines: BAFF and IL-21 were added in a cytokine mix to easier distribute cytokines in 
wells. 50 µL of 100 ng/well of BAFF and 50 µL of 50 ng/well of IL-21 were used. The 
desired concentration of cytokines had to be multiplied by four because it would be diluted 




gain 50 L of cytokine mix per well. CpG was added in medium to gain 50 µL of 4 x 0,6 
µg/mL per well and added directly to cultures. 
Culture: 50 L of each solution was added to each well. For control samples, each solution 
left out was replaced with medium so that each well contained a total of 200 µL. Figure 5.2 
shows a general set up for two wells. The ELISA plates were then incubated at 37 °C, 7,5% 
CO₂, 6,6% O₂.  
 
  
4.5 Sorting cells using a MACS-system 
MACS (magnetic-activated cell sorting) is a system for sorting cells using columns with 
antibodies and a magnet. MACS was used to enrich the population of B-cells. Antibodies for 
CD22, an antigen found frequently on B-cells, were used. The magnet would hold on to the 
cells that attached to anti-CD22 (later called the column "adherent cell" population), and the 
adherent population will therefore mostly consist of B-cells. If the number of cells exceeded 
50 million, the solution was divided in two and then run separately, to not exceed the column 
capacity.  
For sorting, PBMC was transferred to vials and then centrifuged 4 minutes at 400 x g, 
supernatant was discarded. The cells were resuspended to 160 L culture medium and left on 
ice for the rest of the experiment to prevent them from absorbing the antibodies. Antibody 
was added (40 L anti-CD22/sample), and then left in fridge for 15 minutes. The cells were 
washed to remove any leftover antibodies as follows: 4 mL PBSA 0,2% was added to each 
Figure 5.2: General set up of culture. 
A: B-cells/PBMC in culture with EL-4-B5 and cytokines. B: Control sample without 




vial, then centrifuged for 4 minutes at 400 x g, 4°C. The supernatant was discarded, and cell 
pellet flicked to detach from vial. Medium was added to gain 3 mL cell suspension.  
A MACS LS column and magnet (Miltenyi Biotec, Germany) was used for the cell sorting. 
The MACS column was placed in the magnet and rinsed with 3 mL PBSA 0,2%. The cells 
were added and the non-adherent cells (flow-through) collected in a vial. The column was 
then rinsed 3 times with 3 mL PBSA 0,2% to remove all non-adherent cells. The adherent 
cells (that attached to the magnet) were transferred to a vial by removing the column from the 
magnet and placing it in the vial, then adding 5 ml culture medium and vigorously flushing 
out the column adherent cells using a sterile plunger provided with the MACS column. 
 
4.6 Flow cytometry/FACS 
Flow cytometry is a commonly used procedure for detecting antigens and sorting cells. Flow 
cytometry was performed multiple times, here follows a general description of the 
preparations. For description on how to run the procedure, check the producer’s manual and 
follow local guidelines. FlowJo software (Becton, Dickinson & Company, USA) was used for 
analysing the results. Fluorochrome-conjugated antibodies were used for flow cytometry and 
fluorescence-activated cell sorting (FACS). PE (Phycoerythrin) and FITC (Fluorescein 
isothiocyanate) were the main fluorochromes, but also APC (allophycocyanin) and PE-A-
F610 (Phycoerythrin alexa fluor 610) were used. Figure 5.3 shows an example of vials used 





Figure 5.3: Example of vials prepared for flow cytometry.   
In this example there are 3 different cell samples after sorting PBMC with 
MACS (pre-sort, flow through and adherent). Vial 1-3 are compensating 
solutions for calibration. Vial 4-6 are solutions made to detect CD19 and 




Flow cytometry for detecting antigens: The cells were resuspended in medium to gain 50 L 
per vial. A minimum of 100 000 cells were distributed per vial. Fluorochrome-conjugated 
antibodies were added to PBSA 0,2% to gain 50 µL/vial (see list of materials). If more than 
one fluorochrome was needed, compensating samples were made to calibrate the flow 
cytometer. All solutions were left on ice to prevent the cells from absorbing the antibodies. 50 
L antibody mixed with medium and 50 L cell suspension was added to vials and left on ice 
for 30 minutes. The leftover antibodies were washed off by using the same method as 
described in removing antibodies for MACS. 200 L PBSA 0,2% was added to each vial and 
flow cytometry was performed with BD LSRFortessa (Becton, Dickinson & Company, USA). 
Flow cytometry for sorting cells (FACS): FACS was performed to sort cells based on the 
antigens. The preparations were mostly the same as above with a few adjustments. The cell 
count was larger, therefor a bigger volume of antibodies (twice the normal) and PBSA 0,2% 
(10 mL instead of 3 mL) were used. 40 L PBSA 0,2% was added to compensating samples 
and 400 L medium with 30% FBS was added to sorting samples so that the cells would 
survive for longer. Vials containing only medium were prepared to sort cells into. The 
compensating samples were used to calibrate and then the cell samples were sorted with BD 
FACSaria III (Becton, Dickinson & Company, USA). 
 
4.7 ELISA 
ELISA (enzyme-linked immunosorbent assay) was used to detect antibodies against TT. The 
method uses ELISA plates consisting of 96 wells that ensure a good environment for antigen-
antibody interaction. An antibody conjugated to an enzyme binds to antigens and changes 
colour to a substrate (see figure 5.4). A standard solution was made to calculate concentration 
of anti-TT in samples.  
A 1 g/mL antigen solution was made from stock and coating buffer (carbonate/bicarbonate 
buffer). ELISA plates were coated with antigens by adding 100 L to each well using a multi-
channel pipette. The plate was covered in adhesive foil and left in fridge (at 4ºC) over night. 
The coating solution was discarded and then washed 3 times as followed: 250 L washing 




to remove remaining drops. 200 L of PBSA 1% was then added to each well to block 
remaining antigens. The plate was covered in adhesive foil and left for 2 hours in room 
temperature. Dilutions for standard solution were made with PBSA 0,2% (see figure 5.5). 
Each tube was vortexed before performing the next step. The sample containing anti-TT was 
diluted in a similar way. 
100 L of each solution was placed in wells. The wells were covered in adhesive foil and left 
in room temperature for 1 hour, then washed 3 times with 250 L washing buffer as described 
earlier. Tablets containing 5 mg p-nitrophenyl phosphate (pNPP; Pierce Biotechnology, USA) 
were diluted in 5 mL of the accompanying substrate buffer per tablet. 100 L pNPP solution 
was added to each well and incubated in the dark for 20 minutes or until sufficient colour 
developed. 50 L 3M NaOH was added to stop the substrate reaction. A spectrophotometer at 
405 nm was used to measure optical density and Excel was used for analysing the results. The 
concentration and related absorbance of standard solution (tetagam) was used to make a 
standard curve. Linear regression was used to find a trend line, and the concentration of anti-
TT was calculated.  
 
 
Figure 5.4: Principles of ELISA for detecting anti-TT.    
1-4 show steps in performing ELISA. First wells are coated with antigens over-night. Sample is 
added and antibodies specific to antigen will attach. A secondary antibody conjugated to an 
enzyme is added and bind to primary antibodies if present. Substrate is added and changes 







ELISpot is a method used for detecting antibody secreting cells. Plates were coated with TT 
antigen or goat anti-IgG capture antibody (see figure 5.6). TT would show cells producing 
specific anti-TT antibodies and goat anti-human IgG show all cells producing IgG antibodies. 
Each sample was made in 3 parallels.  
The ELISpot plate was prepared by using the following method: 15 L 35% ethanol was 
added to each well to soften the membrane. The plates were washed 4 times by adding 100 
L PBS per well and discarded. The remaining drops were removed by tapping the plate on 
paper towels. 50 L of 10 g/mL TT or goat anti-human IgG was added to respective wells. 
The plate was covered with adhesive foil and left in the fridge (at 4ºC) over night. The 
samples were washed 5 times using 100 µL PBS as described earlier. 120 L blocking buffer 
(PBS + 2% FBS) was added to block remaining antigens. The plate was then left for 1 hour at 
room temperature.  
Tube  Dilution Final IU/mL  
(= concentration) 
Volume antigen Volume 
PBSA 
0,2% 
 Tetagam P 250   
S1 1:100 2,5 10 L of stock tetagam P 990 L 
S2 1:10 000 0,025 10 L of tube 1 990 L 
S3 1: 20 000 0,0125 500 L of tube 2 500 L 
S4 1: 40 000 0,00625 500 L of tube 3 500 L 
S5 1: 80 000 0,003125 500 L of tube 4 500 L 
S6 1:160 000 0,00156 500 L of tube 5 500 L 
S7 1: 320 000 0,000781 500 L of tube 6 500 L 
S8 1: 640 000 0,000391 500 L of tube 7 500 L 
S9 1: 1 280 000 0,000195 500 L of tube 8 500 L 
S10 1: 2 560 000 0,0000977 500 L of tube 9 500 µL 
Figure 5.5: Dilutions for standard solution.    
Standard solutions were made by transferring volume of tetagam stock or other tube (listed 
under “volume antigen”) and adding PBSA 0,2% (listed under “volume PBSA 0,2%”). 
Only S3-S10 was used for measuring optical density. Concentration in IU/mL and 




The cell solution was prepared by resuspending cells to 100 L per well. A positive control 
containing cells known to produce antibodies and a negative control of EL-4-B5 was 
prepared. Blocking buffer was discarded and 100 L of cell suspension was added to the 
respective wells. The plate was left over night in a 7,5% CO2 incubator (at 37°C).  
The plate was washed 5 times with 120 µL washing buffer (PBS 0,01% tween 20) and then 
once with 120 L PBS. The secondary antibody (goat anti-human IgG Fc alkaline 
phosphatase (ALP) conjugate) was prepared to gain 1 g/mL. The antibody was sterile 
filtrated and 50 L was added to each well. The plates were then left in the incubator for 2 
hours and then washed again 5 times with 120 L washing buffer and once with 120 L PBS. 
Then 50 L of filtrated substrate (nitro-blue tetrazolium chloride/5-bromo-4-chloro-3-
indolyphosphate p-toluidine salt (BCIP/NBT)) was added per well and left for 10 minutes in 
the dark. When spots appeared on the plate, it was rinsed for 3 minutes with tap water. The 
plastic film sealing the bottom of the plate was removed, and the plate was rinsed for another 
for 3-5 minutes. The plate was left to dry in room temperature over-night. Immunospot 3 
(CTL Cellular Technology Limited, USA) was used for counting and image acquisition used 
for photographing the ELISpot plate. 
Figure 5.6: Principles of ELISpot for detecting IgG and TT secreting cells.    
Wells are coated with TT or goat anti-human IgG. Samples containing plasmablasts 
producing antibodies are added. Anti-TT will only bind TT, all other IgG antibodies will 
bind goat-anti human IgG. Cells and unbound antibodies are washed off. Detection antibody 
conjugated to enzyme is added and bind to antibody if present. Substrate changes colour by 





To establish an in vitro cell culture system in which memory B-cells can be activated to 
differentiate into antibody-secreting cells, cultures with blood cells from donors and a 
selection of stimulating agents were made. Cell populations were analysed with flow 
cytometry. B-cell activation was confirmed with antibody production measured with ELISA, 
and/or detection of plasmablasts with ELISpot.  
 
5.1 Stimulation of memory B-cells to produce anti-TT 
antibodies depends on blood cells from TT immunized 
donors and T-cells expressing CD40L 
5.1.1 Do the EL-4-B5 cells express CD40L? 
To find out if the EL-4-B5 cells expressed CD40L essential in activation of B-cells, flow 
cytometry was performed. Antibodies for CD40L in humans and mice were used to detect 
CD40L. PBMC and anti-CD19 were used for control samples.  
The results show that EL-4-B5 cells express CD40L as expected (fig. 6.1). Sample F shows 
EL-4-B5 cells binding anti-CD40L from mouse and the large curve indicates that most cells 
express CD40L. Sample E shows that the human anti-CD40L cannot bind to the EL-4-B5. 
This indicates that the antibody is very specific for CD40L from humans only, and therefor 
will not bind the EL-4-B5 which originates from mice. Sample D is a positive control since 
CD19 is specific to B-cells. The PBMC contains other cells than B-cells, this is supported by 







5.1.2 Does plasma from the blood donors contain anti-TT antibodies?  
To confirm that the donors had been immunized with TT, ELISA was performed on plasma 
extracted from buffy coat. TT was used to coat plates, FBS was used for negative control and 
PBSA for blanc samples. The mean of each sample was calculated and the blanc subtracted. 
Standard solutions (Tetagam) were used to find the concentration of anti-TT in plasma. 
Plasma from donor 2 and 3 share standard solutions and therefore also standard curve. The 
results indicate that all donors were immunized with TT (fig. 6.2). Donor 1 had a high level of 
anti-TT and donor 3 a low level.  
Figure 6.1: The EL-4-B5 cells express CD40L. 
PBMC or EL-4-B5 cells were reacted with PE-conjugated anti-human or anti-mouse CD40L, 
or anti-human CD19 and analysed with flow cytometry.  
The line indicates the area for antibody-binding cells. Samples D and F are positive, and the 





   
 
 
5.2 Can we stimulate B-cells from PBMC in cultures with EL-4-
B5, CpG and antigen?    
To investigate if B-cells from PBMC could be activated to antibody producing plasmablasts, 
cultures were made. PBMC from donor 1 and different combinations of EL-4-B5, CpG and 
antigen were cultured for 9 days. Antigen (TT) was added in 5 different concentrations (1, 2, 
4, 8 and 16 ng/mL). EBV was used as a positive control sample. The surface solution from 
each sample was extracted on day 3, 6 and 9 and then analysed for anti-TT with ELISA.  
The results show very low values of anti-TT indicating that B-cells were not activated (shown 
in the appendix). The standard solutions have appropriate values indicating that the ELISA 
method has been done correctly. For the EBV control samples, 1/3 of wells had a positive 
result of 0,831 in the undiluted day 9 result. This might indicate that there are too few B-cells 
in the other wells to be activated.  
 
Figure 6.2: All donors were immunized with TT.  
Plasma from all three donors were analysed for anti-TT by ELISA. The standard solutions 
were used to make a standard curve and linear regression to find a trendline. The diagram to 




5.3 Can we further optimize B-cells? 
5.3.1 Can we sort B-cells from PBMC using MACS? 
To enrich B-cell populations for further experimenting MACS was performed. CD22 
antibodies were used to detect and sort B-cells from PBMC. The pre-sort, flow through and 
adherent cell samples were analysed with flow cytometry. Anti-CD19 was used to detect B-
cells.  
The adherent population had a much higher proportion of CD19 binding cells than the pre-
sort and flow through (fig. 6.3). There were still some B-cells in the flow through sample 
indicating that some B-cells were lost in the process. More than 90% of the adherent samples 
were B-cells for all donors, implying that the MACS was successful in enriching B-cell 
population for further research. 
 
Figure 6.3: MACS column adherent cells were highly enriched for B-cells (CD19+).   
B-cells were sorted from PBMC by MACS using anti-CD22. A flow cytometry was 
performed to compare the adherent, flow through and pre-sort populations. PE-
conjugated CD19 antibodies were used to detect B-cells.  
The lines separate the population of CD19+ cells from CD19- cells. The number is the 




5.3.2 Do all donors have B-cells expressing isotype switched 
immunoglobulins? 
In the flow cytometry of adherent cells from donor 1, IgM and IgG antibodies were used to 
look for memory (IgG+) and naïve (IgM+) B-cells. The results show a big population of IgM 
positive cells (fig. 6.4). The IgG binding population should be in the area marked IgG+, but 
no clear population can be found. FlowJo calculated that IgM + cells were about 97-98%, and 
IgG + cells are 2-3%, but the numbers remain uncertain since there is no clear division 
between the populations. The results indicate that either the flow cytometry was not able to 
detect the IgG+ memory cells, or donor 1 had very few (if any). This would indicate that 
donor 1 was not suited for experimenting on humoral immune responses. 
 
Another flow cytometry was performed on all PBMC’s (PBMC1, PBMC2 and PBMC3) to 
ensure the donors had memory cells. Antibodies for IgM, IgG and IgA were used for 
quantifying the different populations. Note that this experiment was performed on PBMC 
whereas the results displayed in figure 6.4 is performed on adherent cells and therefore 
missing the CD19 negative population. 
Flow cytometry confirm IgG+ populations for all donors (fig. 6.5). FlowJo was used to 
quantify the population of CD19+ (B-cells) and IgG+ (memory B-cells) cells. 2,6% of B-cells 
in PBMC1 were IgG+, 6,3% for PBMC2 and 13,4% for PBMC3. Results for IgM and IgA 
can be found in the appendix. The results show that all donors had memory cells, but the size 
of the populations varies. Donor 1 had a smaller and less defined IgG+ population than the 
other donors.  
Figure 6.4: Few B-cells express IgG in donor 1.   
Adherent cells from donor 1 were reacted with FITC-conjugated anti-IgM or anti-IgG and 
analysed with flow cytometry. The gates indicate the expected location of IgG and IgM + and - 









5.4 Can we stimulate isolated B-cells in cultures with EL-4-B5, 
cytokines and antigen in vitro? 
5.4.1 Can we activate isolated B-cells in vitro to differentiate into 
antibody-secreting cells?  
To activate B-cells, cultures with adherent cells from PBMC1 were combined with antigen 
(TT), tetagam, irradiated EL-4-B5 and cytokines (IL-21 and BAFF). EL-4-B5 and adherent 
cells alone were used for control samples. The cells were incubated for 1 week and then 
FACS was used to analyse and sort plasmablast populations. ELISpot was used to detect IgG 
and anti-TT secreting cells.  
Microscopy of the cells after 1 week incubation indicate that the culture was successful in 
activating B-cells (fig. 6.6). Cells in culture are increased in number and size compared to 
adherent and EL-4-B5 cells alone.  
Figure 6.5: All donors had B-cells expressing IgG. 
PBMC from all donors were reacted with PE-conjugated anti-CD19 and FITC-conjugated 
anti-IgM, anti-IgA or anti-IgG and analysed with flow cytometry. The gates indicate IgG+ 






FACS was performed on cells from culture to analyse and sort cell populations. Anti-CD19 
was used for detecting B-cells and anti-IgM to exclude naïve cells. Anti-CD27 and anti-CD38 
were used to detect plasmablasts. PBMC was used as control sample. From flow cytometry it 
was hard to define IgM- and CD38- populations (fig. 6.7). There were more CD27+ cells in 
the culture than the control sample (PBMC), but a population of CD27++/CD38++ cells was 
not easy to distinguish (fig. 6.7C). Four populations were sorted by FACS (see figure 6.8). 
Figure 6.6: Isolated B-cells cultured with irradiated EL-4-B5 cells increased in cell 
number compared to B-cells alone.   
Adherent cells from donor 1 were cultured 1 week with EL-4-B5, TT, tetagam and 
cytokines (IL-21 and BAFF). Adherent cells and EL-4-B5 cells were used for control 
samples. Photos from microscopy. Sample C did originally contain the same number of 
cells as A and B combined.  
Figure 6.7: There were more CD27+ cells in culture compared to control.  
The culture and control PBMC were added PE-A-F610-conjugated anti-CD19, FITC- 
conjugated anti-IgM, PE-conjugated anti-CD27 and APC-conjugated anti-CD38 and 
analysed with flow cytometry.  
A: lymphocyte population in culture sample. B: CD19+ and IgM- (memory cell) 




ELISpot was performed to detect antibody secreting cells. Row 1-3 were coated with IgG to 
detect cells secreting polyclonal IgG antibodies. Row 4-6 were coated with TT to detect cells 
secreting TT-specific antibodies. The positive control contained a PBMC sample known to 
produce IgG (not anti-TT) and the negative control contained EL-4-B5. Column a and b had 
more than 200 cells per well secreting IgG (fig. 6.8). The count decreased from a to d as 
expected, because there are fewer plasmablasts in the later sorts. There were only a few cells 
secreting TT-specific antibodies. The results show that the method managed to activate B-





Figure 6.8: The culture contained antibody-secreting cells.   
Plasmablasts sorted by FACS were added to ELISpot plates coated with IgG or TT. After 
incubation for 1 day, goat-anti human IgG Fc-ALP and BCIP/MBT substrate were used to 
detect cells secreting antibodies.  
Each dot represents 1 antibody-secreting cell. Image acquisition was used for 
photographing wells. The number next to the wells are the number of cells counted by 
Immunospot 3. The figures to the left show the gates used for sorting. Sorted events are 
identified by consecutive gating of events in the upper and bottom plots. In the figure, only 





5.4.2 Is EL-4-B5 and antigen essential to activate B-cells? 
Similar cultures were made to investigate if EL-4-B5 and antigen were essential for activating 
B-cells. The cultures consisted of isolated B-cells from PBMC2 or PBMC3 with either TT 
only, TT + tetagam or no antigen, and with or without EL-4-B5. All wells were added 
cytokines (IL-21 and BAFF) and left for 8 days in incubator. The cultures were analysed as in 
the previous experiment, supplemented with ELISA to detect anti-TT in the supernatant from 
culture. The microscopy showed increased number of cells in cultures with EL-4-B5 (fig. 6.9 
for donor 3). There were no clear differences between wells with TT, TT + tetagam and no 
antigen. Cultures of cells from donor 2 showed a similar pattern (not shown).  
 
FACS was performed as in the previous experiment to analyse the culture and sort 
plasmablasts. Samples from donor 3 had the greatest number of cells and will be discussed in 
detail. Results from donor 2 are found in the appendix. Plasmablasts were expected to be 
found in the CD27++/CD38++ population, and this population was sorted (P3). A population 
of CD27+/CD38- was sorted for comparison (P4).  
Figure 6.9: Isolated B-cells in culture with irradiated EL-4-B5 had a higher number 
of cells compared to cultures without EL-4-B5.  
Adherent cells were cultured 8 days with cytokines (IL-21 and BAFF) and/or irradiated 




The results show differences in the CD27++/CD38++ populations (fig. 6.10). Samples 
containing EL-4-B5 and EL-4-B5 + TT seemed to have greater populations than samples 
without EL-4-B5, indicating that EL-4-B5 is important for activation of B-cells. Note that the 
samples contain different numbers of cells and cannot be compared directly. The results are 
analysed later in combination with results from ELISpot (fig. 6.12).  
 
 
ELISpot was performed with P3 (CD27++/CD38++) and P4 (CD27+/CD38-) populations. 
For donor 2 the samples without EL-4-B5 were not sorted because of low number of cells. 
Samples were added to plates coated with IgG or TT to differentiate cells secreting antibodies 
specific to TT and polyclonal IgG antibodies.  
Figure 6.10: There were more CD27++/CD38++ cells in samples with EL-4-B5.  
Cultures of isolated B-cells from donor 2 and 3 were added PE-A-F610 conjugated anti-
CD19, FITC-conjugated anti-IgM, PE-conjugated anti-CD27 and APC-conjugated anti-
CD38 and analysed with flow cytometry. The figure shows results of adherent cells from 
donor 3. 
The gates indicate CD27+/CD38- population (left) and CD27++/CD38++ population 
(right). Arrows in figure A indicate the P3 (CD27++/CD38++) and P4 (CD27+/CD38-) 





The results show many plasmablasts producing anti-IgG, but few producing anti-TT (fig. 
6.11). Twice as many wells contained cells from donor 3, therefore the cell count is higher 
than for donor 2. The wells were added different numbers of cells so the cell count must be 
analysed further, but it provides an indication of in which samples B-cell were activated. 
Wells containing EL-4-B5 had more IgG secreting cells compared to wells without EL-4-B5. 
The highest numbers were for samples containing TT + tetagam, indicating that this was the 
best combination for B-cell activation. There were more cells in P3 than P4 indicating that the 
FACS effectively sorted the plasmablast populations based on CD27 and CD38. There are a 
few artifacts in the plate coated with TT, and the cell count cannot be trusted. There are few 
anti-TT plasmablasts detected and no conclusions can be made.  
The results suggest that B-cells were activated to plasmablasts secreting unspecific IgG 
antibodies. EL-4-B5 is essential and EL-4-B5 in combination with TT + tetagam seems the 







Comparing the number of cells in P4 with P3 ensures a relative and more reliable cell count. 
The P3/P4 ratio shows that there are in fact most plasmablasts in samples with EL-4-B5 (fig. 
6.12). TT + tetagam has slightly more plasmablasts than TT and EL-4-B5 only (0,66 vs. 
0,54/0,48). All samples without EL-4-B5 have lower ratios.  
From FACS the exact cell count in each sample is known, and therefore how many cells were 
added to ELISpot. These numbers can be used to find how many of the CD27++/CD38++ 
cells (plasmablasts) were detected as antibody-secreting cells. Approximately 15% of sorted 
plasmablasts in P3 with EL-4-B5, TT + tetagam were secreting IgG (fig. 6.12). The other 
samples with EL-4-B5 were also high compared to samples without EL-4-B5. Samples with 
Figure 6.11: EL-4-B5 is essential for activating B-cells to IgG secreting cells, TT + tetagam 
seems the most beneficial combination of antigens. Very few cells secreting anti-TT was 
detectable.  
Cultures of P3 and P4 from donor 2 and 3 were added to ELISpot plate coated with IgG or TT. 
After 1 day incubation, goat-anti-human IgG Fc-ALP and substate was used to detect IgG or 
anti-TT producing cells.  
Figures at the top indicate gates used for sorting P3 and P4.  
Each dot represents 1 antibody-secreting cell. The numbers next to the wells are the number of 




only TT had the highest percentage of plasmablasts secreting IgG, possibly an effect due to 
low count. Similar measurements for plasmablasts secreting anti-TT cannot be done because 
of few cells. The results support previous findings that EL-4-B5 is essential for activating B-
cells, and that antigen increases the activation, especially when crosslinked. Results for donor 
2 shows similar results, however % of IgG secreting cells for EL-4-B5 and TT + tetagam are 
lower than those of EL-4-B5 alone and EL-4-B5 + TT (shown in the appendix).  
Sample Cells sorted in 
P3 
Cells sorted in 
P4 
Ratio of cells 
P3/P4 
% of cells 
sorted in P3 
secreting IgG 
EL-4-B5 + TT 1204 2194 0,54 13,1 
EL-4-B5 + TT + 
tetagam 
2020 3042 0,66 14,9 
EL-4-B5 1696 3565 0,48 12,4 
TT 53 922 0,06 26,4 
TT + tetagam 67 1214 0,06 4,5 
B-cells only 41 774 0,05 4,9 
 
5.4.3 Are these results confirmed by differences in antibody-production? 
To confirm the results from the ELISpot, an ELISA was performed to detect anti-TT in the 
supernatant from the cultures. The mean blanc value (0,087) was subtracted from each value 
and 0,01 was used as cut off for positive results. The results for samples from donor 3 are 
compiled in figure 6.13. The result for donor 2 and the untreated data can be found in the 
appendix. Differences in absorbance indicate that EL-4-B5 induced B-cell activation. For 
wells containing EL-4-B5; 8/16 wells containing TT and 9/16 wells containing no antigens, 
were positive for anti-TT. For wells without EL-4-B5 all samples were negative.  
Figure 6.12: EL-4-B5 in combination with TT and tetagam is most efficient for 
activating B-cells.  
CD27++/CD38++ (P3) and CD27+/CD38- (P4) populations were sorted with FACS. Both 
samples were analysed with ELISpot for detection of antibody secreting cells. Numbers 





All wells containing TT + tetagam were positive indicating that there is some background 
absorbance due to reaction with tetagam. The values were divided in “low OD” and “high 
OD” in attempt to divide samples containing anti-TT and samples with background 
absorbance only. 0,150 was used as cut-off between low and high OD. The cut-off was 
chosen because it seemed to fit; all values in “high OD” were more than 0,013 higher than the 
values in “low OD” and the variance in the low group was 0,023. The variance in the “high 
OD” was grater indicating absorbance + anti-TT. 10/16 wells containing EL-4-B5 were in the 
“high OD” group versus 1/16 of wells without EL-4-B5. The results support that EL-4-B5 is 
most important for activating B-cells. The results show no significant difference between 
samples containing TT + tetagam, TT only and no antigen.  
Donor 3 
TT TT + tetagam No antigen 
1 2 3 4 5 6 7 8 9 10 11 12 
EL-4-
B5 
A + + + + High High High High + + + + 
B   +  Low High Low Low  +  + 
C + + + + High High High High + + + + 




E     Low Low Low Low     
F     Low Low Low Low     
G     Low High Low Low     





Figure 6.13: ELISA confirms that EL-4-B5 is important for activating B-cells to 
produce anti-TT.  
Supernatant from cultures were added to plates coated with TT. Goat anti-human IgG Fc 
conjugated to ALP and pNPP were used to detect anti-TT. The absorbance for each value 
was found with a spectrophotometer at 405 nm. The mean blanc value was subtracted from 
all values. Figure shows results from donor 3.  
Positive values are defined as ≥0,01 (indicated “+”) and negative values < 0,01. For 
samples with tetagam, values ≥ 0,150 are defined as high OD (marked “High”) and values  





The goal for our research was to activate B-cells in vitro to develop a method for further 
research on humoral immune responses. Memory B-cell responses against the antigen TT was 
measured. TT is well suited for testing methods since most people have been vaccinated 
against TT, and blood samples can be received from anonymous donors. No patient 
information was required for the research.  
To activate and stimulate memory cells, B-cells were combined with T-cells expressing 
CD40L (EL-4-B5 cells) and cytokines (IL-21 and BAFF) or CpG. A disadvantage with the 
method is that all B-cells receive the same stimuli. In vivo, antigen-specific T-cells will 
search for B-cells specific to the same antigen, and only this cell will receive stimulatory 
signals and differentiate. This is harder to mimic in an in vitro experiment.  
 
6.1 EL-4-B5 cells were essential for B-cell activation in our 
cultures 
The results show that EL-4-B5 cells are important for B-cell activation. The flow cytometry 
from cultures with EL-4-B5 shows bigger populations of plasmablasts, and ELISpot confirms 
a higher number of antibody-secreting cells. ELISA also confirms that anti-TT is more often 
detected in wells containing EL-4-B5. EL-4-B5 are mutated T-cells, and it has been shown 
that CD40L in the EL-4-B5 is responsible for activating B-cells (15). Flow cytometry 
confirmed that the EL-4-B5 cells used for our experiments expressed CD40L. CD40L activate 
CD40 on B-cells and, along with cytokines, enhances B-cell survival and differentiation to 
plasma and memory cells (3). Other studies support our finding that EL-4-B5/CD40 is 
essential for activating B-cells (5, 7, 8, 15, 16). It is found that continuous CD40 activation 
can inhibit B-cells from differentiating into plasmablasts (5). Our EL-4-B5 cells continuously 
display CD40L, but still induced B-cells. A few B-cells were activated without the CD40L 
signal as shown in the results. This is supported by the fact that people with T-cell 





6.2 Antigen enhanced general B-cell activation 
In vivo, antigens are essential for activating B-cells (1). Antigens stimulate B-cells through B-
cell receptor and stimulate T-cells to express CD40L. Only B-cells that bind to antigen and 
CD40L will be activated (1). In our experiments, all B-cells were stimulated by CD40L (and 
cytokines), resulting in B-cell activation regardless of antigen-specificity. Therefore, we 
examined antigens stimulating effect and if crosslinking the antigen enhanced B-cell 
activation. 
The experiments show that cultures containing antigen in addition to EL-4-B5 are more likely 
to activate B-cells. Tetagam was added to crosslink the TT to increase its function (6). 
According to the results, TT + tetagam are slightly more likely to stimulate B-cells than TT 
alone. Other studies support our findings that antigen enhances activation of B-cells (6, 8, 11). 
It is suggested that antigen primarily lowers the threshold for activation of specific B-cells 
(6). This is supported by our findings since antigen is not enough to activate B-cells alone, but 
induces activation in combination with CD40L and cytokines.  
The results show a general activation of B-cells, and multiple memory B-cells are stimulated. 
Antigen is important for activation of antigen-specific memory cells and production of 
antigen-specific antibodies (6, 8). In vivo, TT would have induced TT-specific memory B-
cells to become anti-TT producing plasmablasts. TT-specific memory B-cells are only a small 
percentage of all memory cells, and because of the general activation, other memory cells 
were also activated. It was expected an increase in TT-specific plasmablasts in comparison to 
other memory cells, but this increase was most likely too small to be measured. In the culture 
of B-cells from donor 1, there are some anti-TT secreting cells supporting that some anti-TT-
specific memory cells have been activated, possibly induced by TT. For this experiment all 
samples contained antigen, so we cannot distinguish if antigen was necessary to get anti-TT 
secretion or not. In the culture with B-cells from donor 2 and 3, almost no anti-TT secreting 
cells are detectable, and no conclusion could be made.  
The ELISA detects anti-TT from supernatant, indicating that there are some anti-TT secreting 
cells present. The results show increased anti-TT production in cultures with EL-4-B5, 
indicating that EL-4-B5 stimulated anti-TT specific memory B-cells. Cultures with TT, TT + 




antigen seem to induce EL-4-B5 stimulated activation of B-cells, but we cannot decide its 
function in antigen-specific activation. 
Nonoyama et al. managed to stimulate B-cells to produce antibody-specific antibodies in 
culture with antigens, direct B-T-cell contact via CD40 and cytokines (IL-10)(8). Possible 
reasons for the results in our study are that there were few TT-memory cells, or anti-TT 
plasmablasts could simply not be detected. Donor 2 and especially donor 3, had lower levels 
of anti-TT in serum, and therefore perhaps fewer TT-specific memory cells. This could 
explain why anti-TT secreting cells could not be found in these samples. This is supported by 
the fact that donor 1 had more anti-TT secreting cells and a higher level of anti-TT in serum. 
Since anti-TT was detected with ELISA, this show that there are some anti-TT secreting cells 
present in the cultures with EL-4-B5. This indicates that we did not manage to detect these 
cells with ELISpot, perhaps because there were too few or because ELISA had a higher 
sensitivity.  
 
6.3 Activated B-cells were not detected from the first culture 
The method used in the first culture failed to measure antibody production in the supernatant, 
indicating that B-cells were not activated. Our suggestion was that there were too few B-cells 
to be activated because of the results of the control samples. EBV is well known to stimulate 
activation and expansion of B-cells in vitro (17). Alternatively, if all control samples were 
negative, this could indicate that something went wrong before or during incubation. If all 
samples with EBV were positive, it would indicate that stimulation in the other samples were 
not enough to activate B-cells. Our results show that only one sample of EBV was positive, 
therefore we suggested that there were too few B-cells to be activated in the other samples. 
There could also be something else wrong with the B-cells from donor 1 which was 
investigate further.  
Another possible explanation is that the positive result was random, and that B-cells were not 
stimulated. We had already proven that the EL-4-B5 expressed CD40L necessary to stimulate 
B-cells. CpG is known to stimulate activation of B-cells in vitro (5, 10-12). CpG contains 
DNA strands and stimulate cells by enhancing production and secretion of cytokines (12). 




differentiation and antibody secretion (5). In the further experiments, cytokines such as IL-21 
and BAFF was used instead of CpG, and this alteration could be why we managed to activate 
B-cells.  
Only anti-TT-specific antibodies were measured in the first culture, so other antibodies could 
have been present. In later experiments, ELISpot shows plasmablasts secreting antibodies 
other than anti-TT. Unspecific memory B-cells could also be activated in the first culture. 
However, in the later experiments ELISA was successful in detecting anti-TT from cultures, 
indicating that the later cultures had a better combination of stimulating agents for activation 
of B-cells.  
 
6.4 Inter-donor variability 
The preparations revealed different levels of anti-TT in serum between donors. All donors had 
levels above the protective level of 0,01 IU/mL (4). For donor 1, ELISA measured a high 
level (13,8 IU/mL), but after looking at the experiment, we predict the actual antibody 
concentration was lower because of the dilution already made when isolating plasma (from 
buffy coat). Our estimate is therefor that the level of anti-TT for donor 1 is ≈ 9,2 IU/mL. 
When isolating PBMC for donor 2 and 3 this was accounted for. The value is still higher than 
for donor 2 (0,73 IU/mL) and 3 (0,025 IU/mL). Farzad et al. has measured levels of 0,06 – 1,0 
IU/mL in a population before a booster vaccine and 16-32 IU/mL 14 days after (18). 
Compared to our results, this indicate that donor 1 has recently been immunized with TT 
through vaccination. For donor 2 and 3 the immunization happened longer ago. Even though 
the level for donor 3 is higher than 0,01 IU/mL, there could be fewer TT-specific memory 
cells, explaining why ELISA could not detect significant numbers of cells secreting anti-TT 
specific antibodies.  
The results also showed various levels of anti-Ig binding cells in PBMC between donors. IgG 
was most important for our research since memory cells are essential for producing 
plasmablasts. Donor 3 had the highest level of IgG+ B-cells. 13,4% of immunoglobulin 
binding cells were IgG+, more than twice the percentage for donor 2 and more than 5 times 




cells of the 3, and therefore perhaps most suitable for experiments on antigen-specific 
humoral immune responses.  
Donor 1 had few IgA and IgG binding cells and a high number of IgM binding cells 
compared to the other two. This pattern is found in an inherited immune deficiency disorder 
called hyper-IgM syndrome (1, 19). The cause is a defect in CD40L leading to impairment in 
the isotype shift from IgM to the other groups of immunoglobulins, resulting in high or 
normal levels of IgM and low or absent levels of IgA, IgG and IgD. The varying levels of Ig+ 
cells found in hyper IgM syndrome could help explain some of our results. The low level of 
IgG+ cells could help explain why we had difficulties activating B-cells in the first culture. In 
the next culture plasmablasts were detected, but the flow cytometry showed abnormal results. 
Comparing flow cytometry from the first and second FACS, more defined populations can be 
seen of both IgM+ and IgM- cells, and CD27++/CD38++ cells in samples from donor 2 and 3 
(see figures 6.7 and 6.10). For donor 1 there is one big population of cells with different 
amounts of IgM, and IgM+ and – populations cannot be distinguished. A CD27+ population 
can be found, but CD38+ and - populations are blended. The high level of IgM and low level 
of IgG and IgA could help explain these results for donor 1.  
The conclusion is that our research suggests that donor 1 had the best basis for analysing TT-
specific immune responses, but few memory cells. Donor 3 had many memory cells to 
examine humoral responses, but possibly few TT-specific. In further experiments we suggest 
choosing a recently immunized (high anti-TT in serum) donor with high or normal levels of 
IgG+ cells.   
 
6.5 Other methods for activating B-cells 
We managed to activate isolated B-cells in combination with EL-4-B5, IL-21 and BAFF, but 
there could be other cells and cytokines to consider in developing a method. Some sources 
indicate that B-cells in culture with other non-B-cells are more likely to differentiate to 
plasmablasts (5). We found that there were not enough memory B-cells in PBMC, but when a 
method is in place this could be investigated further. Cytokines such as IL-21 (5),  IL-10 (8), 




agents could be compared. CpG in addition to these cytokines should also be considered, 
although one should be aware of the CD40L inhibiting effect explained earlier (5).  
Analysing methods should also be considered. Flow cytometry was suitable for detecting 
CD40L in EL-4-B5 cells. ELISA has been found to be sensitive for detecting anti-TT in 
serum (18), and we predict that the divergent levels that were measured are due to actual 
differences in anti-TT. Flow cytometry confirmed that the MACS did enrich B-cell 
population using anti-CD22 antibodies.  
The flow cytometry and FACS showed well defined populations of plasmablasts in samples 
from donor 2 and 3. Plasmablasts were defined as B-cells (CD19+ lymphocytes), IgM- and 
CD27++ and CD38++. We confirmed that B-cells were stimulated to differentiate to 
plasmablasts, and identified defined plasmablast populations from culture. ELISpot was later 
used to confirm antibody-secreting cells in the sorted samples. We conclude that CD38 and 
CD27 are suited for distinguishing plasmablasts, also shown in other studies (5). It is possible 
to estimate how many of the CD27++/CD38++ cells sorted by FACS were antibody secreting 
cells, and this technology will be important for further research. Comparing number of cells 
secreting antigen-specific antibodies and antigen-unspecific antibodies will be of interest. For 
our study, a low percentage of antibody-secreting cells from sorted plasmablasts were found. 
The highest ratio of plasmablasts secreting IgG is 14,9% in culture with isolated B-cells from 
donor 3, EL-4-B5 and TT + tetagam (see table 6.1). Some cells are expected to be lost in the 
process of ELISpot and some produce other immunoglobulins than IgG. The low percentage 
could however indicate that cells do not survive or that ELISpot is not able to detect all 
plasmablasts. ELISpot could therefore be less suited for confirming B-cell activation. 
ELISpot in combination with ELISA analyses both cells and supernatant from culture, and we 
predict that these methods combined give a good estimate.   
 
6.6 Further research 
The purpose of our research was to look at antigen-specific humoral immune responses 
associated with FNAIT. We have shown that B-cell activation is possible in culture with 
CD40L, antigen and cytokines. CD40L is most important for B-cell activation and 




were producing IgG antibodies but not anti-TT. In order to look at the antigen-specific 
immune responses, we suggest isolating antigen-specific B-cells. We predict that our method 
was efficient but had too few antigen-specific B-cells to prove antigen-specific activation. If 
performed on a population of TT-specific memory B-cells, we would be able to detect more 
anti-TT secreting cells. 
B-cells are only one part of the humoral immune responses. Once a method for activating B-
cells is in place, the next step should be to look at T-cell activation. A method for making T-
cells from PBMC express CD40L would be of interest. Our research on B-cells will then form 
an important basis for further studies, and TT could be used to look at antigen-specific 
responses. In our experiments the EL-4-B5 cells were constantly expressing CD40L, 
precluding linked recognition. By introducing the same antigen to both B- and T-cells, 
activation could be easier. A challenge will be to activate antigen-specific memory T-cells in 
vitro. 
The purpose for developing methods for activating B- and T-cells, is to look at the humoral 
immune responses behind FNAIT. In FNAIT, B- and T-cells in the mother’s circulation is 
activated and stimulated to produce antibodies against HPA-1a. The immunological responses 
behind FNAIT are more complex than those of TT, but when the methods are in place, 
activating B- and T-cells in blood from HPA-1a positive donors could provide essential 
knowledge of the maternal immune response that causes FNAIT. Hopefully we will someday 










The purpose of this study was to look at antigen-specific humoral immune responses 
associated with FNAIT. We specifically looked at the B-cell, and the goal was to find a 
method for activating antigen-specific B-cells in vitro and to identify and isolate activated B-
cells secreting antibodies. Our research showed that we managed to stimulate isolated B-cells 
in culture with cytokines, antigen and CD40L from EL-4-B5 to differentiate to antibody-
secreting plasmablasts. Plasmablasts were identified as CD19+, CD27+, CD38+ cells and live 
cells were isolated by FACS to confirm antibody-secretion. CD40L was most important in the 
activation, and antigen had a synergic effect. However, the antibodies produced were mostly 
unspecific IgG, indicating an antigen-unspecific activation of B-cells. Further research is 
needed to find a method for activation of antigen-specific B-cells. We suggest isolating 
antigen-specific memory B-cells, and then integrating the method explained in this paper. 
Tetanus toxoid can be used as antigen for further development of methods, but donors should 
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List of materials: 
 Material Use Information Origin 
Regular lab 
resources 
Cell culture medium Cell culture 90% IMDM (iscove’s 
modified Dulbecco’s 
medium) + 10% FBS 
Gibco 
 Coating buffer  ELISA, ELISpot Carbonate/bicarbonate 
buffer  
(0,80g Na₂CO₃ 1,465g 
Na₂HCO₃) 
Molarity: 20mM, pH: 
9,2 
Immunological 
research group at UiT 
 Freezing medium  Freezing cells 90% FBS (fetal bovine 
serum) + 10% DMSO 
(dimethyl sulfoxide) 
WAK – chernie Medical 
GmbH 
 PBS (phosphate buffered 
saline) 
Buffer 0,14M NaCl, 2,7mM 
KCl, 10mM phosphate 
buffer, pH 7,2 
Medicago AB (09-9499-
100) 
 PBS + 10% FBS Blocking buffer 
ELISpot 
90% PBS + 10 % FBS Immunological 
research group at UiT 
 PBSA 0,2%   98,8% PBS + 0,2% BSA 
(bovine serum albumin) 
Immunological 
research group at UiT 
 PBSA 1% Blocking buffer 
ELISA 
99% PBS + 1% BSA Immunological 
research group at UiT 





 Washing buffer  ELISA, ELIspot PBS 0,05% tween 20 Sigma -aldrich, 
Immunological 




BD FACSAria III FACS  Beck Dickingson and 
company 
 BD LSRFortessa Flow cytometry  Beck Dickinson and 
company 
 Centrifuge (Rotina 420 R) Centrifuging 
components 
 Hettich 
 Hemocytometer Estimate cell count Burker chamber Karl Hecht 
 MACS (Magnetic-activated 
cell sorting) 




BAFF (B-cell activating 
factor) 
Stimulate cells Ref: PHC1674 Invitrogen 





 Buffy coat Isolate PBMC From random, 
anonymous adult 
donors. Consented for 
scientific purposes 
The blood bank of the 
University hospital of 
Northern Norway.  
 CpG (ODN 2006) Stimulate cells N. 74301513 Integrated DNA 
technologies 





 EL-4-B5 Display CD40L Mutated murine 
thymoma cells 
Cell line based on R. H. 
Zubler’s research (14) 
 Ethanol 35% ELISpot Wetting the 
membranes 




 IL-21 (Interleukin 21) Stimulate cells Ref: PHC0215 Gibco 
 Lymphoprep Isolating PBMC Density gradient: 
1.077g/mL.  
Serumwerk 
 pNPP (p-nitrophenyl 
phosphate) 
ELISA Substrate for ELISA Pierce biotechnology 
 Tetagam P Crosslinking TT, 
Standard curve in 
ELISA 
Antibody against TT. 
Desired concentration: 
2,5 IU/mL 
Anti-TT from the 
university hospital of 
Northern Norway  




Antibodies CD8 FITC  








 CD19 APC  
(Mouse anti-human CD19 
allophycocyanin 
conjugated) 





Beckson, Dickinson and 
company 
 CD19 PE  
(human CD19 
phycoerythrin conjugated)  





 CD19 PE-A-F610  
(Human CD19 
phycoerythrin alexa fluor 
610 conjugated) 





 CD22  
(human CD22) 
Isolating B-cells by 
MACS 
Mat. No: 120-000-257 
 
Miltenyi biotec 









 CD38 APC  






Used for 1. FACS 
Cat: 5555462 
 
Beckson, Dickinson and 
company pharmingen 











 CD40L PE  
(human CD40L 
phycoerythrin conjugated) 
Detecting CD40L in 
flow cytometry 
Cat: 555700 Beckson, Dickinson and 
company pharmingen 
 CD40L PE  
(mouse CD40L 
phycoerythrin conjugated) 
Detecting CD40L in 
flowcytometry 
Cat: 561719 Beckson, Dickinson and 
company pharmingen 
 Goat anti-human IgG  








Ref: A18832 Invitrogen 
 IgA FITC (polyclonal rabbit 
anti-human IgA fluorescein 
isothiocyanate conjugated) 





 IgG FITC  
(polyclonal rabbit anti-
human IgG fluorescein 
isothiocyanate conjugated) 





 IgM FITC  
(polyclonal rabbit, anti-
human IgM fluorescein 
isothiocyanate conjugated) 
Detecting IgM+ cells 







 Additional results 
Table 10.1: Untreated data from ELISA for detecting levels of anti-TT in 
plasma from donor 1 
 
1 2 3 4 5 6 
A 1,391 1,363 1,382 2,516 2,282 2,139 
B 0,868 0,872 0,865 2,133 1,901 1,927 
C 0,581 0,58 0,62 1,781 1,673 1,575 
D 0,323 0,324 0,324 1,296 1,2 1,185 
E 0,2 0,202 0,204 0,889 0,775 0,804 
F 0,144 0,141 0,145 0,574 0,537 0,542 
G 0,116 0,108 0,116 0,34 0,318 0,332 
H 0,09 0,073 0,071 0,071 0,072 0,072 
 
Explanation to table 10.1: 
 Standard solution Plasma 
1 2 3 4 5 6 
A 1:20 000 1:100 
B 1:40 000 1:200 
C 1:80 000 1:400 
D 1:160 000 1:800 
E 1:320 000 1:1600 
F 1:640 000 1:3200 
G 1:1 280 000 1:6400 
H 1: 





Table 10.2: Untreated data from ELISA for detecting levels of anti-TT in 
plasma from donors 2 and 3. 
 7 8 9 10 11 12 
A 1,403 1,403 0,23 0,216 0,087 0,091 
B 0,889 0,888 0,131 0,146 0,071 0,083 
C 0,551 0,569 0,136 0,127 0,092 0,105 
D 0,34 0,342 0,09 0,095 0,092 0,122 
E 0,208 0,213 0,095 0,088 0,081 0,111 
F 0,148 0,154 0,092 0,082 0,073 0,081 
G 0,107 0,106 0,088 0,102 0,073 0,083 






Explanation to table 10.2: 
 Standard solution Plasma No antigen 
 7 8 9 10 11 12 
A 1:20 000 Plasma donor 2 1:800 
B 1:40 000 Plasma donor 2 1:1600 
C 1:80 000 Plasma donor 2 1:3200 
D 1:160 000 Plasma donor 2 1:6400 
E 1:320 000 Plasma donor 3 1:800 
F 1:640 000 Plasma donor 3 1:1600 
G 1:1 280 000 Plasma donor 3 1:3200 






Tables 10.3, 10.4, 10.5 and 10.6: Untreated data from ELISA of 
supernatant from culture of PBMC 1 
10.3: Day 3 (diluted 1:10) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,099 0,096 0,087 0,094 0,107 0,091 0,091 0,088 0,106 0,038 0,034 0,035 
B 0,096 0,083 0,082 0,084 0,079 0,079 0,085 0,078 0,078 0,033 0,033 0,034 
C 0,105 0,099 0,099 0,092 0,106 0,1 0,101 0,091 0,115 0,032 0,034 0,033 
D 0,089 0,085 0,086 0,087 0,082 0,082 0,082 0,082 0,082 0,035 0,034 0,033 
E 0,089 0,079 0,081 0,079 0,076 0,076 0,082 0,078 0,074 0,033 0,033 0,033 
F 0,086 0,087 0,081 0,082 0,082 0,077 0,085 0,082 0,08 0,035 0,037 0,033 
G 0,085 0,09 0,085 0,086 0,088 0,091 0,084 0,082 0,084 0,033 0,034 0,035 
H 0,089 0,085 0,085 0,086 0,085 0,093 0,091 0,084 0,089 0,035 0,032 0,031 
 
10.4: Day 6 (Diluted 1:10) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,102 0,091 0,088 0,089 0,102 0,098 0,091 0,096 0,113 0,031 0,032 0,031 
B 0,083 0,084 0,082 0,081 0,085 0,084 0,087 0,075 0,084 0,032 0,03 0,03 
C 0,112 0,096 0,093 0,095 0,102 0,102 0,104 0,097 0,116 0,032 0,03 0,03 
D 0,079 0,08 0,076 0,08 0,084 0,095 0,081 0,075 0,083 0,031 0,033 0,034 
E 0,083 0,078 0,078 0,082 0,078 0,08 0,08 0,074 0,083 0,033 0,033 0,032 
F 0,09 0,079 0,083 0,083 0,077 0,084 0,083 0,089 0,084 0,033 0,037 0,033 
G 0,089 0,086 0,111 0,08 0,081 0,083 0,089 0,08 0,095 0,033 0,033 0,035 






10.5: Day 9 (diluted 1:10) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,099 0,098 0,091 0,112 0,102 0,106 0,109 0,1 0,101 0,029 0,033 0,044 
B 0,106 0,112 0,085 0,099 0,102 0,091 0,123 0,092 0,106 0,029 0,03 0,028 
C 0,121 0,126 0,114 0,133 0,127 0,125 0,129 0,136 0,131 0,029 0,028 0,031 
D 0,109 0,106 0,104 0,1 0,12 0,11 0,112 0,118 0,123 0,03 0,029 0,031 
E 0,097 0,094 0,083 0,102 0,113 0,104 0,108 0,108 0,103 0,032 0,03 0,029 
F 0,098 0,114 0,099 0,108 0,109 0,093 0,112 0,119 0,103 0,032 0,027 0,029 
G 0,097 0,109 0,11 0,104 0,105 0,105 0,111 0,108 0,104 0,031 0,033 0,028 
H 0,102 0,099 0,089 0,101 0,103 0,095 0,109 0,158 0,097 0,027 0,031 0,032 
 
10.6: Day 9 (undiluted) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,097 0,098 0,101 0,102 0,158 0,145 0,098 0,097 0,093 3,255 3,282 3,884 
B 0,102 0,1 0,1 0,102 0,134 0,112 0,118 0,106 0,113 3,399 3,117 3,248 
C 0,121 0,121 0,122 0,142 0,129 0,14 0,134 0,137 0,122 2,941 2,941 3,242 
D 0,121 0,098 0,105 0,123 0,11 0,117 0,101 0,123 0,126 2,255 2,264 2,292 
E 0,094 0,084 0,093 0,108 0,105 0,117 0,085 0,081 0,085 1,258 1,353 1,311 
F 1,527 1,479 1,525 0,085 0,082 0,079 0,086 0,089 0,083 0,736 0,784 0,783 
G 0,09 0,107 0,098 0,095 0,081 0,087 0,098 0,083 0,084 0,435 0,463 0,452 
H 0,098 0,096 0,084 0,095 0,08 0,085 0,098 0,921 0,103 0,269 0,282 0,27 
 
Explanation for tables 10.3, 10.4, 10.5 and 10.6 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1, 2, 3 (1 ng/mL), 5 1, 2, 3 (1 ng/mL), 4 1, 3 (16 ng/mL), 5x2 Standard:  
1:20 000* 
B 1, 2, 3 (2 ng/mL), 5 1, 2, 3 (2 ng/mL), 4 1, 3 (16 ng/mL), 4, 5 1:40 000* 
C 1, 2, 3 (4 ng/mL), 5 1, 2, 3 (4 ng/mL), 4 1, 4, 5x2 1:80 000* 
D 1, 2, 3 (8 ng/mL), 5 1, 2, 3 (8 ng/mL), 4 1, 2, 4, 5 1:160 000* 
E 1, 2, 3 (16 ng/mL), 5 1, 2, 3 (16 ng/mL), 4 1, 2, 5x2 1:320 000* 
F Serum donor 1 1:3200*  1, 5x3 1:640 00* 
G    1:1 280 000* 
H Blanc* Blanc* 1, 4, 5, 6 1:2 560 000* 
1: PBMC1, 2: EL-4-B5, 3: TT with concentration, 4: CpG, 5: medium, 6: EBV.               





Figure 10.7: Flowcytometry of IgA- and IgM-binding cells in PBMC1, 
PBMC2 and PBMC3 
 
 
Figure 10.8: Percentages of IgM, IgA and IgG positive B-cells in PBMC1, 
PBMC2 and PBMC3.  
 PBMC1 PBMC2 PBMC3 
IgG 2,6 % 6,3 % 13,4 % 
IgM 87,7 % 80,3 % 65,4 % 
IgA 2,7 % 5,6 % 14,8 % 
Comment: FlowJo is used for estimating a count of B-cells (CD19 PE) and IgM, IgA and IgG 





Figure 10.9: Results from FACS of B-cells from donor 2 in culture with 
cytokines and different combinations of EL-4-B5, TT and tetagam. 
 
Figure 10.10: Results from ELISpot and FACS for donor 2.  
Sample Cells sorted in 
P3 
Cells sorted in 
P4 
Ratio of cells 
P3/P4 
% of cells 
sorted in P3  
secreting IgG 
EL-4-B5 + TT 261 242 1,08 16,1 
EL-4-B5 + TT + 
tetagam 
271 192 1,41 7,4 
EL-4-B5 137 169 0,81 11,7 
 
Figure 10.11: Untreated data from ELISA of anti-TT in culture from donor 
3.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0,101 0,122 0,102 0,112 0,269 0,254 0,247 0,253 0,106 0,106 0,218 0,134 
B 0,083 0,08 0,46 0,08 0,216 0,241 0,21 0,219 0,083 0,302 0,096 0,484 
C 0,107 0,123 0,11 0,103 0,264 0,252 0,244 0,245 0,116 0,106 0,111 0,402 
D 0,081 0,079 0,078 0,08 0,306 0,215 0,219 0,222 0,091 0,079 0,081 0,08 
E 0,077 0,076 0,077 0,077 0,216 0,211 0,205 0,211 0,083 0,077 0,081 0,076 
F 0,081 0,083 0,083 0,081 0,22 0,217 0,214 0,22 0,082 0,079 0,09 0,083 
G 0,085 0,096 0,086 0,084 0,224 0,246 0,22 0,228 0,086 0,085 0,09 0,088 




Explanation to figure 10.11 

























Figure 10.12: Untreated data from ELISA of anti-TT in culture from donor 
2.  
 1 2 3 4 5 6 
A 0,088 0,08 0,406 0,441 0,082 0,09 
B 0,075 0,072 0,375 0,389 0,072 0,071 
C 0,097 0,089 0,432 0,426 0,089 0,1 
D 0,079 0,075 0,405 0,415 0,079 0,073 
E 0,088 0,078 0,399 0,419 0,08 0,073 
F 0,084 0,087 0,393 0,398 0,085 0,085 
G 0,091 0,085 0,317 0,317 0,103 0,09 
H 0,102 0,094 0,191 0,19 0,102 0,091 
 
 
Explanation to figure 10.12 




























Figure 10.13: Results from ELISA of anti-TT in culture from donor 2.  
 TT TT + tetagam No antigen 
1 2 3 4 5 6 
EL-4-B5 A   High High   
B   High High   
C +  High High  + 
D   High High   
No EL-4-B5 E   High High   
F   High High   
G   High High +  
H +  Low Low +  
Comment: Positive values are >0,01 (indicated with +) and negative values < 0,01.  
Values for tetagam a cut-off at 0,150 is used to divide into a high OD group (High) and low 
OD group (Low).  
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